Synapse - Myeloma

Results (1016)

Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens

Meeting Abstract

Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma

Meeting Abstract

Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
Blood (2023)

Fulltext@MSK | Save

Low target antigen expression mediates resistance to BCMA CAR T cell therapy

Meeting Abstract

Perica, K.; Nataraj, S.; Sjojstrand, M. L.; Nagel, K.; Pavkovic, E.; Payson, E.; Cuenca, A.; Patel, A.; Chung, D.; Mailankody, S.; more...
Blood (2023)

Fulltext@MSK | Save

Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies

Meeting Abstract

Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study

Meeting Abstract

Raab, M. S.; Hänel, M.; Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3

Meeting Abstract

Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Response rates and outcomes in newly-diagnosed multiple myeloma (NDMM) patient subgroups receiving RVd±ASCT plus lenalidomide maintenance until progression in the phase 3 determination trial

Meeting Abstract

Hassoun, H.; Jacobus, S. J.; Voorhees, P. M.; Zonder, J. A.; Lonial, S.; Raje, N.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Reeves, B.; more...
Bone Marrow Transplantation (2023)

Fulltext@MSK | Save

Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma

Meeting Abstract

Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Raje, N.; Leleu, X.; Lesokhin, A. M.; Mohty , M.; Nooka, A.; Leip, E.; Conte, U.; Vlqueira, A.; Manier, S.
American Journal of Hematology (2023)

Fulltext@MSK | Save

Pooled analysis of MagnetisMM studies: Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to B-cell maturation antigen (BCMA)-directed therapies

Meeting Abstract

Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maise, C.; Arnulf, A.; Larson, S. M.; Asya, V. Y. N.; Leleu, X.; Karlin, L.; more...
American Journal of Hematology (2023)

Fulltext@MSK | Save